RxDoctor Payments Data

Niraj Pandit, MD

Interventional Cardiology · Tallahassee, FLNPI 1740270198

Payments from drug & device makers

$20,324in general payments, 2019–2025

Across 323 payments — averaging $62.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$10K
  • Medtronic$5K
  • Boston Scientific$819
  • Abiomed$781
  • Penumbra, Inc.$750
  • Shockwave Medical, Inc$496
  • plus $2K from 28 others

What the payments were for

  • Speaking & faculty fees$9,68048%
  • Travel & lodging$2,17411%
  • Food & beverage$8,35641%
  • Education$1131%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,324 in reported general payments places this provider in the 65th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$166,352
Medicare patients
522
Services billed
1,378

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban97$104,802
EntrestoSacubitril/Valsartan77$97,544
XareltoRivaroxaban27$29,109
JardianceEmpagliflozin14$16,937
ClopidogrelClopidogrel Bisulfate169$2,173
Metoprolol Tartrate149$1,043
Losartan Potassium97$1,022
Nebivolol Hcl11$864
Metoprolol Succinate60$798
Lisinopril55$669
Atorvastatin Calcium70$648
Valsartan11$546
Carvedilol62$490
Irbesartan13$447
Amlodipine Besylate51$383

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$205$104,80297 claims
NovartisEntresto$10,445$97,54477 claims
Johnson & JohnsonXarelto$90$29,10927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Tallahassee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →